Biotech · Private company
Elevar Therapeutics
Track this companyFree. Adds Elevar Therapeutics to your Dealase workspace and tells you when its record changes.
Clinical trials71 recruiting or active
Pipeline programs9From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline9
- RivoceranibPhase 3 · Gastric CancerClinicalTrials.gov · fetched Nov 12, 2026
- LirafugratinibPhase 2 · FGFR2 Gene Fusion/RearrangementClinicalTrials.gov · fetched Nov 12, 2026
- RivoceranibPhase 2 · Adenoid Cystic CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- RLY-4008Phase 2 · FGFR2 AmplificationClinicalTrials.gov · fetched Nov 12, 2026
- ApatinibPhase 1 · CancerClinicalTrials.gov · fetched Nov 12, 2026
- NivolumabPhase 1 · CancerClinicalTrials.gov · fetched Nov 12, 2026
- RivoceranibPhase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- RivoceranibPhase 1 · Metastatic Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- Trifluridine/TipiracilPhase 1 · Metastatic Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials7
- A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or RearrangementPHASE2 · RECRUITING · started Jun 4, 2026ClinicalTrials.gov NCT07359820 · fetched Nov 12, 2026
- A Study Comparing Four Different Rivoceranib Tablets in Healthy ParticipantsPHASE1 · COMPLETED · started Dec 30, 2021ClinicalTrials.gov NCT05287360 · fetched Nov 12, 2026
- REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid TumorsPHASE1_PHASE2 · COMPLETED · started Sep 2, 2020ClinicalTrials.gov NCT04526106 · fetched Nov 12, 2026
- A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)PHASE2 · TERMINATED · started Jan 22, 2020ClinicalTrials.gov NCT04119453 · fetched Nov 12, 2026
- A Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC)PHASE1 · TERMINATED · started Nov 18, 2019ClinicalTrials.gov NCT04073615 · fetched Nov 12, 2026
- A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic CancerPHASE1 · COMPLETED · started Dec 22, 2017ClinicalTrials.gov NCT03396211 · fetched Nov 12, 2026
- A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric CancerPHASE3 · COMPLETED · started Mar 14, 2017ClinicalTrials.gov NCT03042611 · fetched Nov 12, 2026